Chorioamnionitis and Culture-Confirmed, Early-Onset Neonatal Infections

BACKGROUND: Current guidelines for prevention of neonatal group B streptococcal disease recommend diagnostic evaluations and empirical antibiotic therapy for well-appearing, chorioamnionitis-exposed newborns. Some clinicians question these recommendations, citing the decline in early-onset group B streptococcal disease rates since widespread intrapartum antibiotic prophylaxis implementation and potential antibiotic risks. We aimed to determine whether chorioamnionitis-exposed newborns with culture-confirmed, early-onset infections can be asymptomatic at birth. METHODS: Multicenter, prospective surveillance for early-onset neonatal infections was conducted during 2006–2009. Early-onset infection was defined as isolation of a pathogen from blood or cerebrospinal fluid collected ≤72 hours after birth. Maternal chorioamnionitis was defined by clinical diagnosis in the medical record or by histologic diagnosis by placental pathology. Hospital records of newborns with early-onset infections born to mothers with chorioamnionitis were reviewed retrospectively to determine symptom onset. RESULTS: Early-onset infections were diagnosed in 389 of 396 586 live births, including 232 (60%) chorioamnionitis-exposed newborns. Records for 229 were reviewed; 29 (13%) had no documented symptoms within 6 hours of birth, including 21 (9%) who remained asymptomatic at 72 hours. Intrapartum antibiotic prophylaxis exposure did not differ significantly between asymptomatic and symptomatic infants (76% vs 69%; P = .52). Assuming complete guideline implementation, we estimated that 60 to 1400 newborns would receive diagnostic evaluations and antibiotics for each infected asymptomatic newborn, depending on chorioamnionitis prevalence. CONCLUSIONS: Some infants born to mothers with chorioamnionitis may have no signs of sepsis at birth despite having culture-confirmed infections. Implementation of current clinical guidelines may result in early diagnosis, but large numbers of uninfected asymptomatic infants would be treated.

[1]  R. Polin,et al.  Reappraisal of guidelines for management of neonates with suspected early-onset sepsis. , 2015, The Journal of pediatrics.

[2]  Johannes B. Reitsma,et al.  Clinical signs to identify late-onset sepsis in preterm infants , 2013, European Journal of Pediatrics.

[3]  R. Polin.  Management of Neonates With Suspected or Proven Early-Onset Bacterial Sepsis , 2012, Pediatrics.

[4]  D. McIntire,et al.  Intrapartum Evidence of Early-Onset Group B Streptococcus , 2012, Obstetrics and gynecology.

[5]  L. Lugli,et al.  Intrapartum antibiotic prophylaxis failure and group-B streptococcus early-onset disease , 2011, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[6]  B. Poindexter,et al.  Early Onset Neonatal Sepsis: The Burden of Group B Streptococcal and E. coli Disease Continues , 2011, Pediatrics.

[7]  S. Schrag,et al.  Group B streptococcal disease in infants: progress in prevention and continued challenges. , 2010, Clinics in perinatology.

[8]  W. Schaffner,et al.  Evaluation of universal antenatal screening for group B streptococcus. , 2009, The New England journal of medicine.

[9]  B. Stoll,et al.  Prolonged Duration of Initial Empirical Antibiotic Treatment Is Associated With Increased Rates of Necrotizing Enterocolitis and Death for Extremely Low Birth Weight Infants , 2009, Pediatrics.

[10]  A. Spitzer,et al.  Empiric Use of Ampicillin and Cefotaxime, Compared With Ampicillin and Gentamicin, for Neonates at Risk for Sepsis Is Associated With an Increased Risk of Neonatal Death , 2006, Pediatrics.

[11]  P. Sánchez,et al.  Early-onset group B streptococcal infection after a combined maternal and neonatal group B streptococcal chemoprophylaxis strategy. , 2003, Pediatrics.

[12]  Stark Ar.  超出生体重児に対する早期デキサメサゾン投与の有用性 : National Institute of Child Health and Human Development Neonatal research Network報告 (海外誌掲載論文の和文概要とそれに対するコメント) , 2001 .

[13]  P. Azimi,et al.  The effectiveness of risk-based intrapartum chemoprophylaxis for the prevention of early-onset neonatal group B streptococcal disease. , 2001, American journal of obstetrics and gynecology.

[14]  P. Visintainer,et al.  Histologic Chorioamnionitis, Antenatal Steroids, and Perinatal Outcomes , 2000, Obstetrics and gynecology.

[15]  A. Schuchat.  Neonatal group B streptococcal disease--screening and prevention. , 2000, The New England journal of medicine.

[16]  B. Stoll,et al.  Risk Factors and Opportunities for Prevention of Early-Onset Neonatal Sepsis: A Multicenter Case-Control Study , 1999, Pediatrics.

[17]  A. Schuchat,et al.  Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. The Active Surveillance Study Group. , 1994, The Pediatric infectious disease journal.

[18]  W. Ledger,et al.  The Changing Perinatal and Maternal Outcome in Chorioamnionitis , 1979, Obstetrics and gynecology.

[19]  J. Neu,et al.  Manipulation of the intestinal microbiome in newborn infants. , 2014, Advances in nutrition.

[20]  K. Puopolo.  The Burden of Invasive Early-onset Neonatal Sepsis in the United States, 2005–2008 , 2012 .

[21]  S. Schrag,et al.  Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[22]  A. Schuchat,et al.  Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. , 1994, Epidemiologic reviews.